Antibody drug conjugates (ADC) that bind to CD37 proteins
AssigneeAgensys, Inc.
InventorsDaniel Sousa Pereira, Faisal Hayat Malik, Josh Snyder, Leslie Renee Butterworth, Ssucheng Jeff Hsu, Peng Yang, Claudia Isabel Guevara
Life of this patent
Estimating the term…
Abstract
Antibody drug conjugates (ADC's) that bind to CD37 protein and variants thereof are described herein. CD37 exhibits a distinct and limited expression pattern in normal adult tissue(s), and is aberrantly expressed in the cancers listed in Table I. Consequently, the ADC's of the invention in some embodiments provide a therapeutic composition for the treatment of cancer.
Claims19
An antibody drug conjugate comprising an anti-CD37 antibody or antigen binding fragment thereof conjugated to 3 to 5 units of monomethyl auristatin E (MMAE) via a linker, wherein the antibody or antigen binding fragment thereof comprises a heavy chain variable region comprising complementarity determining regions (CDRs) having the amino acid sequences of the CDRs in the heavy chain variable region sequence set forth in SEQ ID NO:
- 7 and a light chain variable region comprising CDRs having the amino acid sequences of the CDRs in the light chain variable region sequence set forth in SEQ ID NO:
- 8.
A method of treating a CD37 expressing cancer in a subject, comprising administering to said subject an anti-CD37 antibody or antigen binding fragment thereof, wherein the antibody or antigen binding fragment thereof comprises a heavy chain variable region comprising complementarity determining regions (CDRs) having the amino acid sequences of the CDRs in the heavy chain variable region sequence set forth in SEQ ID NO:
- 7 and a light chain variable region comprising CDRs having the amino acid sequences of the CDRs in the light chain variable region sequence set forth in SEQ ID NO:
- 8.
A method of inhibiting growth of cancer cells in a subject, comprising administering to said subject an antibody drug conjugate, wherein the antibody drug conjugate comprises an anti-CD37 antibody or antigen binding fragment thereof, conjugated to 3 to 5 units of monomethyl auristatin E (MMAE) via a linker, and wherein the antibody or antigen binding fragment thereof comprises a heavy chain variable region comprising complementarity determining regions (CDRs) having the amino acid sequences of the CDRs in the heavy chain variable region sequence set forth in SEQ ID NO:
- 7 and a light chain variable region comprising CDRs having the amino acid sequences of the CDRs in the light chain variable region sequence set forth in SEQ ID NO:
- 8.
Dependencies are inferred from the claim text.